Trials / Completed
CompletedNCT02920021
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- AnaptysBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine etokimab safety, tolerability and activity in adult participants with peanut allergy.
Detailed description
This is a multi-center, randomized, double-blind, placebo-controlled, proof of concept study to assess the safety and tolerability of etokimab in adult participants with peanut allergy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etokimab | Humanized monoclonal antibody, administered by intravenous infusion |
| DRUG | Placebo | Administered by intravenous infusion |
Timeline
- Start date
- 2017-01-26
- Primary completion
- 2018-03-30
- Completion
- 2018-03-30
- First posted
- 2016-09-30
- Last updated
- 2023-07-27
- Results posted
- 2023-07-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02920021. Inclusion in this directory is not an endorsement.